FORMULATION, IN VITRO AND IN VIVO EVALUATION OF PALBOCICLIB SOLID DISPERSIONS

Objective: The current research is aimed to enhance the dissolution and bioavailability of Palbociclib by formulating into solid dispersion Methods: dispersions (SD) prepared adopting different methods: Surface technique (SSD1-SSD15), Melt granulation (MG1-MG15) Liquisolid compacts (LSC1-LSC9). All formulations were evaluated for physico-chemical parameters followed in vitro studies. optimised formulation was subjected studies rats. Results: results indicated that satisfactory all parameters. SD liquisolid compact Granulation (LSC1 MG 3) displayed maximum 99.64% 99.58%. FTIR LSC1 no interaction among drug excipients while XRD, SEM amorphous nature formulation. stability study LSC 1 stable over 3 mo. vivo conducted on rats indicate at any time point, plasma concentrations animals administrated with higher than pure drug. Cmax palbociclib 970.76±1.22 ng/ml significant (p<0.05) when compared suspension (105.84±0.19 ng/ml). Tmax both 2.0±0.04 4±0.01 h, respectively. AUC0-∞ 7816.61±1.37 ng. h/ml) 2501.4±1.46 h/ml indicating better systemic absorption from using technique. Conclusion: A enhancement profile melt granules observed Palbocicilib marketed product.